Summary & Overview
CPT 0114U: EsoGuard Methylation Test for Barrett’s Esophagus
CPT code 0114U designates the EsoGuard™ Proprietary Laboratory Analyses (PLA) test from Lucid Diagnostics, a molecular diagnostic that assesses cytosine methylation of esophageal cells collected with a swallowed balloon device to detect methylation of VIM and CCNA1—markers predictive of Barrett’s esophagus. As a PLA code, 0114U is specific to a single manufacturer's test and signals distinct coding, billing, and coverage considerations for molecular diagnostics across payers. Nationally, adoption of PLA-coded tests affects laboratory billing workflows and payer coverage policies for minimally invasive esophageal cancer screening tools.
Key payers addressed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find consolidated information on payer coverage patterns, common billing modifiers used with complex molecular lab services, and clinical context about the EsoGuard™ test’s sampling method and reported results. The publication also provides benchmarks and policy updates relevant to PLA-coded diagnostics, operational guidance on site-of-service considerations, and implications for coding and reimbursement processes. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0114U is a Proprietary Laboratory Analyses (PLA) code for the EsoGuard™ test developed by Lucid Diagnostics. The test uses cytosine methylation analysis of esophageal cells obtained from a swallowed balloon device and applies an algorithm to report the presence or absence of VIM and CCNA1 methylation, a predictor of Barrett’s esophagus.
Service type: Laboratory molecular diagnostic test using methylation analysis of esophageal samples obtained via a swallowed balloon device.
Typical site of service: Outpatient clinic, ambulatory procedure center, or laboratory setting where the swallowed balloon collection device is administered and specimens are processed by the performing laboratory.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with chronic gastroesophageal reflux disease (GERD) and confirmed or suspected columnar-appearing esophagus on endoscopy is evaluated for noninvasive screening for Barrett’s esophagus. A primary care physician or gastroenterologist orders the EsoGuard™ test (reportable with 0114U). The patient swallows a single-use balloon cytology device per manufacturer instructions in an outpatient clinic or ambulatory infusion/diagnostic lab; cells are collected during retrieval of the device and sent to the proprietary laboratory. The laboratory performs cytosine methylation analysis of esophageal cells and runs an algorithm that reports presence or absence of VIM and CCNA1 methylation as a predictor of Barrett’s esophagus. Results are returned to the ordering clinician who integrates the molecular test result with clinical findings (symptoms, endoscopy, biopsy results if available) to guide surveillance or referral to gastroenterology. Typical site of service: outpatient clinic, ambulatory surgery center, or reference laboratory for the analytic component. Typical patient scenario: symptomatic GERD with risk factors (long-standing reflux, age >50, male sex, hiatal hernia) undergoing a minimally invasive screening test when endoscopy is deferred or as an adjunct to endoscopic assessment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When reporting the professional interpretation component separately from the laboratory analytic component (if applicable and payer allows). |
52 | Reduced services | When the test is partially performed or specimen retrieval is incomplete but analytic workup is reduced. |
53 | Discontinued procedure | If the swallowing device deployment is attempted but procedure is terminated for patient safety before adequate specimen obtained. |
59 | Data not provided in the input. | Data not available in the input. |
62 | Two surgeons | When two qualified practitioners are required for device placement due to patient complexity (rare for this test). |
76 | Data not provided in the input. | Data not available in the input. |
80 | Assistant surgeon | When an assistant surgeon documents participation in device placement (rare for this outpatient test). |
22 | Increased procedural services | If significantly more effort or time is required for device placement or specimen collection beyond typical service. |
78 | Unplanned return to the operating/procedure room by the same physician following initial procedure for a related procedure during the postoperative period | When an unplanned repeat attempt to obtain specimen is required shortly after the initial attempt. |
TC | Technical component | When billing only the laboratory analytic component and the facility/lab reports the technical processing. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207Q00000X | Gastroenterology | Performing clinician ordering test and managing follow-up care. |
| 208000000X | General Surgery | May be involved in device placement in select surgical outpatient settings. |
| 208D00000X | Family Medicine | Ordering test for primary care–based screening of at-risk patients. |
| 261QM1000X | Clinical Laboratory | Performing laboratory that conducts the proprietary methylation analysis and reports 0114U. |
| 207RP1001X | Internal Medicine | Internists ordering test for GERD patients and coordinating specialty referral. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
K21.9 | Gastro-esophageal reflux disease without esophagitis | Common indication for screening for Barrett’s esophagus with noninvasive tests like EsoGuard™. |
K22.7 | Barrett's esophagus | Direct target condition that the EsoGuard™ test predicts via methylation markers. |
R12 | Heartburn | Symptom that prompts evaluation for GERD and consideration of Barrett’s screening. |
K44.9 | Diaphragmatic hernia without obstruction or gangrene | Hiatal hernia often coexists with GERD and increases risk for Barrett’s esophagus. |
Z12.11 | Encounter for screening for malignant neoplasm of esophagus | Screening context where molecular tests may be used to stratify need for endoscopy. |
R13.10 | Dysphagia, unspecified | Symptom that may prompt diagnostic evaluation including endoscopy following a positive molecular screen. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
0114U | Cytosine methylation analysis of esophageal cells obtained from swallowed balloon device; algorithmic analysis reporting presence/absence of VIM and CCNA1 methylation (EsoGuard™) | Primary proprietary laboratory analyte code for the EsoGuard™ test; reports molecular marker result used to predict Barrett’s esophagus. |
43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | Diagnostic endoscopy with biopsy performed when EsoGuard™ is positive or when endoscopic evaluation is indicated. |
88305 | Level IV surgical pathology, gross and microscopic examination | Histopathology processing and diagnosis of endoscopic biopsy specimens obtained for confirmation of Barrett’s esophagus. |
81002 | Urinalysis, non-automated, without microscopy | Data not applicable to this procedure; included as none of the additional codes were provided. |
0000U | Data not provided in the input. | Data not available in the input. |